N-Acetyl Selank Amidate (Nasal Spray) Protocol
An end-capped modification of Selank — the same Thr-Lys-Pro-Arg-Pro-Gly-Pro heptapeptide with an N-terminal acetyl group and a C-terminal amide added to resist peptidases. Sold as a 10 mg vial to be made up as an intranasal solution. There are no published studies of the amidate itself: every citation on this page is base Selank, whose own human data are small Russian-language trials. Not FDA-approved.
An end-capped modification of Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro), itself a synthetic analog of the immunopeptide tuftsin with a stabilising Pro-Gly-Pro tail. The acetyl and amide caps are intended to resist peptidases. It is a variant of the Selank we already cover, not a distinct drug, and it has no published literature of its own.
Intranasal only. Typically a 10 mg vial dissolved into a nasal solution, then a few drops or sprays per nostril once or twice daily. There is no validated amidate-specific dose and no published comparison with plain Selank, so the common advice to "use less because it is stronger" rests on chemistry, not measurement. The registered base-Selank trials used roughly 300-900 mcg/day intranasally in 10-14 day courses.
Zero PubMed studies of N-Acetyl Selank Amidate itself. The evidence base is base Selank: positive allosteric modulation of GABA-A binding in rat brain membranes, resting-state fMRI changes in amygdala connectivity in healthy volunteers, improved learning in poor-learning rats, and small Russian-language randomised trials in generalised anxiety disorder and neurasthenia reporting anxiolytic effects comparable to benzodiazepines. An independent 2021 US review classes Selank as poorly studied. Neither Selank nor the amidate is FDA-approved.
Quickstart Highlights
N-Acetyl Selank Amidate (sold as NA-Selank amidate or simply N-acetyl Selank) is an end-capped modification of Selank. Selank is the synthetic heptapeptide Thr-Lys-Pro-Arg-Pro-Gly-Pro — the endogenous immunopeptide tuftsin (Thr-Lys-Pro-Arg) extended with a stabilising Pro-Gly-Pro tail — developed in Russia and studied as an anxiolytic with a mild nootropic component[1][2]. The amidate version caps both ends of that same sequence: an acetyl group on the N-terminus and an amide on the C-terminus.
Those caps are a chemical stability argument — blocking the free amino and carboxyl termini is a standard way to slow the exopeptidases that clip peptides from their ends. Vendors turn that argument into marketing claims that the amidate crosses the blood–brain barrier more easily and is “more potent by weight.” Neither claim has been published. A PubMed search for the acetylated, amidated analog returns no studies of the compound at all (checked 13 August 2026), so there is no head-to-head against plain Selank on potency, duration or brain penetration. Everything cited on this page is base Selank, and base Selank’s own human evidence is a handful of small Russian-language trials[2][3]. An independent 2021 US pharmacology review put it bluntly, calling Selank a poorly studied Russian drug that is nonetheless sold to US consumers[4]. This is an educational reference, not medical advice, and neither compound is FDA-approved.
Supplies Needed
NA-Selank amidate is used as an intranasal solution, so there is no needle and no injection kit. What matters is a correctly dissolved, clearly labelled, well-preserved solution and clean intranasal delivery — knowing the exact concentration is what makes the dose meaningful at all.
Protocol Overview
NA-Selank amidate is a stability-modified analog of Selank. Selank is built from tuftsin, the endogenous immunomodulatory tetrapeptide Thr-Lys-Pro-Arg, extended with Pro-Gly-Pro to slow its degradation — giving the heptapeptide Thr-Lys-Pro-Arg-Pro-Gly-Pro studied as an anxiolytic with mild nootropic effects[1][6]. The amidate adds a second layer of the same idea, capping the termini with an acetyl and an amide.
The honest core of this page is the evidence relationship, and it is unusually stark. The research base is Selank: GABA-A allosteric modulation measured by radioligand binding[1], altered amygdala connectivity on resting-state fMRI in 52 healthy volunteers[5], improved learning in rats with poor baseline learning ability[6], and small Russian randomised trials in anxiety disorders[2][3]. For the amidate itself there is nothing — no pharmacokinetics, no efficacy study, no safety data. It is best understood as a more durable presentation of the same pharmacology, on the assumption, untested, that the pharmacology survives the modification unchanged. Neither is FDA-approved.
Dosing Protocol
Because NA-Selank amidate is intranasal, the “protocol” below is solution strength and application, not a reconstitution ladder for a syringe. These figures are nootropic-market convention, with the base-Selank clinical regimen shown for context. None of them is a validated amidate-specific dose.
| Parameter | Typical | Notes |
|---|---|---|
| Vial | 10 mg lyophilised | Dissolved to make a nasal solution |
| Example strength | 10 mg in 10 mL = 1 mg/mL | A 0.1 mL spray ≈ 100 mcg |
| Frequency | 1–2 sprays/nostril, 1–2× daily | Convention only — no validated dose |
| Route | Intranasal | No injection; the studied route for Selank |
| Base-Selank clinical dose[2][3] | ~300–900 mcg/day × 10–14 days | Selank in anxiety trials, not the amidate |
Why N-Acetyl Selank Amidate draws research interest
These are the directions researchers and the peptide community most often explore N-Acetyl Selank Amidate for — so you know you’re in the right place. They describe what is being studied, not proven benefits, approved uses, or promised results.
Anxiety & stress support
The anxiolytic case rests on small Russian trials of base Selank — the end-capped amidate itself has no published study.
Focus & cognitive performance
Selank improved learning in rats with poor baseline ability; no human cognitive trial exists for either form.
Peptide stability & duration
The acetyl and amide caps are a chemical rationale for peptidase resistance, never measured against plain Selank.
Evidence ranges from early laboratory work to clinical trials depending on the use — the sections below cover the actual data and sources.
A 10 mg lyophilised vial, dissolved into an intranasal solution (some vendors sell it pre-made as a 10 mL spray). No needle, no subcutaneous injection.
The N-acetyl and C-amide caps block the free termini, a standard way to slow exopeptidase breakdown. It is a chemical rationale, not a measured result — no published study tests it.
A few drops per nostril once or twice daily by convention. Clinical base-Selank dosing was course-based — about 300–900 mcg/day for 10–14 days[2][3].
No studies of the analog itself. All data are base Selank: small Russian-language trials plus animal work. Not FDA-approved, and called “poorly studied” in independent review[4].
Dosing & Application
NA-Selank amidate has no injectable dose and no syringe maths — it is an intranasal product, so “dosing” means how strong you make the solution and how many drops, how often. What follows is the conventional usage, stated honestly against the fact that no controlled data exist for the amidate and the clinical figures belong to base Selank[2][3].
Standard / Gradual Approach
In practice, NA-Selank amidate arrives as a 10 mg lyophilised vial. It is dissolved — commonly in bacteriostatic water or a saline/preservative nasal base — and used at a few drops or sprays per nostril, once or twice daily. The convention is to use less than one would of plain Selank, on the reasoning that the end-capping makes the peptide more durable. It is worth being clear that this is a convention built on a chemical expectation, not on any published potency comparison[4].
For scale, the Russian clinical studies dosed base Selank intranasally in courses: roughly 300–900 mcg per day over 10–14 days in generalised anxiety disorder and neurasthenia, given as drops divided between the nostrils[2][3]. Those trials enrolled 60–62 patients and compared Selank with medazepam or phenazepam. They are the closest thing to a dose anchor that exists — and they are for Selank, not the amidate.
The dominant practical variable is concentration. Because the buyer usually reconstitutes the vial, the same “two sprays” can differ by an order of magnitude depending on whether 10 mg went into 1 mL or 10 mL. A 10 mg vial made up to 10 mL gives 1 mg/mL, so a typical 0.1 mL spray actuation delivers about 100 mcg. Working out that number before the first dose is the single most useful thing a user can do, since there is no validated amidate dose-response to fall back on.
Storage Instructions
Keep the sealed lyophilised vial cold — refrigerated for ordinary use, frozen for long storage — and protected from light. Dry peptide is far more stable than peptide in solution, so there is no benefit to dissolving a vial before you intend to use it.
Once made up, treat the nasal solution as perishable: refrigerate it, keep it sealed, and discard it if it becomes cloudy, discoloured or develops an odour. A nasal solution without a proper preservative has a short usable life, and a solution whose concentration you cannot state is not usable at all, because the strength is the entire dose calculation.
Important Notes
These are the points most often lost when NA-Selank amidate is sold as a straightforward “upgrade” to Selank.
- ▪There is no literature on the amidate: a PubMed search for the acetylated, amidated analog returns no studies of the compound (checked 13 August 2026). Every finding cited here — GABA-A modulation, the fMRI work, the anxiety trials — was generated with base Selank[1][2][3][5].
- ▪“More potent” and “crosses the BBB better” are unpublished claims: end-capping is a sound reason to expect peptidase resistance, but no published pharmacokinetic or brain-penetration comparison with Selank exists. Treat the potency claim as a rationale, and if anything a reason for restraint rather than confidence[4].
- ▪Selank’s own base is small and single-tradition: the human trials are Russian-language, 60–62 patients, run by the developing institutes[2][3]. An independent 2021 review in the Journal of Clinical Pharmacology specifically describes Selank as poorly studied and notes it is sold to US consumers as a supplement[4].
- ▪The mechanism is not fully settled: Selank behaves as a positive allosteric modulator of GABA binding in rat brain membranes[1], yet in cultured human neuroblastoma cells it produced no direct change in the mRNA levels of GABAergic-system genes[7]. The GABA story is a binding-level effect, not a demonstrated transcriptional one.
- ▪Intranasal, not injectable: Selank’s human data come from intranasal administration. There is no basis for injecting NA-Selank amidate, and it should not be treated as an injectable peptide despite arriving in a vial that looks like one.
- ▪Know your concentration: because you dissolve the vial yourself, the labelled strength you create is the whole safety margin. Ten milligrams into 1 mL versus 10 mL is a tenfold difference per spray, and there is no validated dose-response to correct against.
How This Works
Selank is a synthetic derivative of tuftsin (Thr-Lys-Pro-Arg), an endogenous tetrapeptide with immunomodulatory activity, extended by a C-terminal Pro-Gly-Pro that markedly slows its breakdown[1]. Its best-characterised action is on the GABAergic system: in rat brain plasma-membrane preparations, Selank altered [3H]GABA binding as a positive allosteric modulator, and its interaction with benzodiazepines was non-cumulative — it partly blocked the modulatory activity of diazepam and olanzapine, suggesting overlapping but non-identical binding sites[1].
In people, the effect is visible at the network level. A resting-state fMRI study in 52 healthy participants compared Selank, Semax and placebo and found group- and condition-dependent differences in functional connectivity between the right amygdala — a key node for anxiety regulation — and right temporal and parahippocampal cortex[5]. In animals, Selank at 300 mcg/kg improved acquisition of a conditioned active avoidance task, with the largest gains in rats that started with poor learning ability[6].
Two honest qualifications belong here. First, the GABA account is incomplete: in cultured IMR-32 neuroblastoma cells Selank produced no direct change in the mRNA levels of 84 GABAergic-system genes, so whatever it does to GABA signalling is not a straightforward transcriptional effect[7]. Second, and more important for this page, all of it describes Selank. The N-acetyl amidate modification is assumed to leave this pharmacology intact while extending its duration — a reasonable inference from the chemistry, and one that has never been checked.
Lifestyle Factors
For anxiety and mood, the interventions with the strongest evidence remain behavioural and clinical: treating anxiety disorders properly, cognitive behavioural therapy, regular aerobic exercise, protected sleep, and reducing alcohol and stimulant load. These carry evidence of a kind that a peptide with no published studies of its own does not.
That is the honest framing for a “daily habits” note here: the proven routes to lower anxiety are unglamorous and well documented, and they avoid the unknowns of self-dosing an unapproved intranasal compound whose strength you set yourself.
Potential Benefits & Side Effects
Evidence tier: no studies of the analog; the meaningful data are base-Selank data, largely animal work plus small Russian-language clinical trials. The “effects” below are Selank findings the amidate is assumed to share; the “considerations” are the honest counterweight.
Reported Effects
- ▪Anxiolysis — Selank clinical data: in a randomised comparison in 62 patients with generalised anxiety disorder and neurasthenia, intranasal Selank produced anxiolytic effects comparable to the benzodiazepine medazepam, with additional antiasthenic and mild psychostimulant effects rather than sedation[2].
- ▪Benzodiazepine-sparing — Selank clinical data: added to phenazepam in 40 patients, Selank brought the response forward and reduced the tranquilliser’s side-effect burden (attention and memory impairment, sedation, asthenia) both during treatment and after withdrawal[3].
- ▪Mechanism — measurable in brain and in vitro: positive allosteric modulation of GABA binding in rat brain membranes[1], and altered right-amygdala functional connectivity on resting-state fMRI in 52 healthy volunteers[5].
- ▪Learning — preclinical: at 300 mcg/kg in rats, Selank improved acquisition of a conditioned active avoidance reflex, most clearly in animals with initially poor learning ability[6].
- ▪What is not established: that NA-Selank amidate specifically does any of this. There are no published studies of the amidate — no efficacy, no pharmacokinetics, no safety — and Selank itself is described as poorly studied in independent review[4].
Common Side Effects
- ▪Generally reported as well tolerated — from Selank use: the Russian trials describe intranasal Selank as well tolerated and notably non-sedating compared with benzodiazepines, without the memory and attention impairment seen with phenazepam[3]. The amidate is assumed similar; it has no safety data of its own.
- ▪Nasal-route effects: as an intranasal product it can cause local nasal irritation, stinging or dripping to the throat, particularly if the solution is concentrated or poorly buffered.
- ▪Concentration risk is the real one: because the user dissolves the vial, an over-concentrated solution makes over-dosing easy, and there is no validated dose-response to signal when you have gone too far.
- ▪A GABAergic compound is not a trivial one: the 2021 review that flags Selank as poorly studied groups it with other GABA-acting agents precisely because that mechanism warrants proper abuse-potential and withdrawal evaluation before consumer sale — evaluation Selank has not had[4].
- ▪Unapproved status and unknown identity: neither Selank nor the amidate is FDA-approved, and a grey-market vial carries no guarantee of identity, concentration or purity. For a compound with no literature, a certificate of analysis is the only evidence of what is actually in it.
How to Apply
Intranasal use is simple, and getting the concentration right matters far more than technique. The steps below describe how a Selank-type nasal solution is typically prepared and used; they are educational, not medical instructions, and they are not a recommendation to use an unapproved compound.
Preparation
- ▪Fix the concentration first: decide and record how much diluent goes into the 10 mg vial. Ten milligrams in 10 mL is 1 mg/mL, so a 0.1 mL actuation is about 100 mcg. Without this number, “two sprays” means nothing.
- ▪Dissolve gently: add the diluent down the side of the vial and swirl rather than shake — peptides are damaged by foaming and vigorous agitation.
- ▪Clear the nose: blow your nose gently so the solution reaches the nasal mucosa instead of sitting on mucus.
Using the Spray
- ▪Deliver into each nostril: one or two sprays or drops per nostril, head slightly forward, breathing gently so the solution stays in the nasal cavity rather than running down the throat.
- ▪Keep the total low: the conventional pattern is once or twice daily, and the widely repeated advice to use less than plain Selank rests on chemistry rather than measurement — which argues for the low end, not the high one.
- ▪Do not chase an effect: avoid frequent redosing. With no validated dose-response for the amidate, there is nothing to justify escalation.
After Use
- ▪Re-cap and refrigerate: reseal the bottle and keep the made-up solution cold and out of light; discard it if it turns cloudy or discoloured.
- ▪Watch for local reactions: mild nasal irritation is common with intranasal peptides; persistent burning or bleeding is a reason to stop.
- ▪Keep expectations proportionate: any effect you attribute to it is inferred from base Selank’s small evidence base, not demonstrated for the amidate.
Recommended Source
For high-purity research peptides, we point researchers to Prime Lab Peptides for N-Acetyl Selank Amidate (Intranasal (10 mg vial)).
Why Prime Lab Peptides?
- ▪Top-rated on Trustpilot: Independently reviewed as the highest-rated peptide lab on Trustpilot — making it the best current source in the USA.
- ▪Third-party tested: Every batch ships with a Certificate of Analysis (COA) confirming purity and composition.
- ▪Consistent quality: ISO-aligned manufacturing and handling keep product integrity reliable batch to batch.
- ▪Cold-chain integrity: Temperature-controlled shipping and storage across the whole fulfilment chain.
- ▪Research-grade purity: Fit for educational and research use that demands high-quality peptides.
Note: Product availability and specifications subject to change. Verify current product details on supplier website.
References
- 1
Protein and Peptide Letters (2018) — Peptide-based anxiolytics: the molecular aspects of heptapeptide Selank biological activityVyunova, Andreeva, Shevchenko & Myasoedov (PMID 30255741). Defines Selank as Thr-Lys-Pro-Arg-Pro-Gly-Pro and shows by radioligand binding in rat brain plasma membranes that it modulates [3H]GABA binding as a positive allosteric modulator; its joint action with benzodiazepines is non-cumulative, and it can block the modulatory activity of diazepam and olanzapine. Base-Selank mechanism, not the amidate. DOI: 10.2174/0929866525666180925144642.
- 2
Zh Nevrol Psikhiatr im S.S. Korsakova (2008) — Efficacy and possible mechanisms of action of the new peptide anxiolytic selank in generalised anxiety disorder and neurastheniaZozulia et al. (PMID 18454096). Randomised controlled trial in 62 patients comparing Selank (30) with medazepam (32), assessed on Hamilton, Zung and CGI scales. Anxiolytic effects were similar, but Selank additionally showed antiasthenic and psychostimulant effects; serum enkephalin activity rose during Selank treatment. Russian-language; administration routes indexed as intranasal and oral. Base-Selank clinical data.
- 3
Zh Nevrol Psikhiatr im S.S. Korsakova (2015) — Optimisation of the treatment of anxiety disorders with selankMedvedev et al. (PMID 26356395). Randomised controlled trial comparing phenazepam monotherapy (30 patients) with phenazepam plus Selank (40 patients) in anxiety-phobic, hypochondriac and somatoform disorders. Adding Selank brought the response forward on HDRS and reduced phenazepam side effects — attention and memory impairment, asthenia, sedation, sexual disturbance — during treatment and after withdrawal. Russian-language. DOI: 10.17116/jnevro20151156133-40.
- 4
Journal of Clinical Pharmacology (2021) — Sedative-hypnotic agents that impact GABA receptors: focus on flunitrazepam, GHB, phenibut, and SelankDoyno & White (PMID 34396551). An independent US review of GABAergic sedative-hypnotics that names Selank specifically, describing phenibut and Selank as “poorly studied Russian drugs with GABAergic mechanisms that are inexplicably sold to US consumers as dietary supplements”, and argues that agents with GABA activity should be evaluated for abuse potential before public access. The strongest available outside-the-tradition appraisal. DOI: 10.1002/jcph.1922.
- 5
Doklady Biological Sciences (2020) — Functional connectomic approach to studying Selank and Semax effectsPanikratova et al. (PMID 32342318). Resting-state fMRI in 52 healthy participants scanned before and 5 and 20 minutes after Selank, Semax or placebo. Group and condition differences appeared in functional connectivity between the right amygdala — a key region for anxiety regulation — and fusiform, inferior/middle temporal and parahippocampal regions. Human mechanistic data for base Selank. DOI: 10.1134/S001249662001007X.
- 6
Neuroscience and Behavioral Physiology (2003) — The optimizing action of the synthetic peptide Selank on a conditioned active avoidance reflex in ratsKozlovskii & Danchev (PMID 14552529). Selank at 300 mcg/kg, given 15 minutes before training over four days, significantly improved acquisition of a conditioned active avoidance reflex, with the clearest gains in rats that started with poor learning ability; compared against piracetam at 400 mg/kg. Preclinical nootropic data for base Selank. DOI: 10.1023/a:1024444321191.
- 7
Frontiers in Pharmacology (2017) — GABA, Selank, and olanzapine affect the expression of genes involved in GABAergic neurotransmission in IMR-32 cellsFilatova et al. (PMID 28293190). Testing 84 GABAergic-system genes in neuroblastoma IMR-32 cells, the authors found no change in mRNA levels under Selank alone, while Selank suppressed the expression changes produced by GABA. An honest qualification of the GABA account: Selank’s effect appears to be at the level of GABA-receptor interaction rather than gene expression. DOI: 10.3389/fphar.2017.00089.
How to apply N-Acetyl Selank Amidate
- 1Blend N-Acetyl Selank Amidate into a clean, water-based serum or cream base at the intended percentage (commonly 3 to 10 percent).
- 2Patch-test on a small area of skin first to check tolerability.
- 3Apply a thin layer to clean, dry skin as documented in cosmetic research (often once or twice daily).
- 4Store the raw powder and the finished serum sealed, cool and away from light; refrigerate water-based serums.
N-Acetyl Selank Amidate — frequently asked questions
How is N-Acetyl Selank Amidate used?
N-Acetyl Selank Amidate is a topical cosmetic peptide applied to the skin as part of a serum or cream — not injected or taken by mouth. It is blended into a water-based base at a chosen percentage and applied to clean skin.
What concentration of N-Acetyl Selank Amidate is typical?
Cosmetic formulations commonly use roughly 3 to 10 percent. Higher is not necessarily better and can affect texture, stability and skin tolerability. The strength shown on this page is a formulation reference, not a dose to inject.
Do I need bacteriostatic water or syringes for N-Acetyl Selank Amidate?
No. As a topical peptide, none of the injectable-peptide supplies (bacteriostatic water, insulin syringes, alcohol swabs) apply — it is dissolved into a serum or cream base and applied to the skin.
How should I store N-Acetyl Selank Amidate?
Keep the raw powder sealed, cool, dry and away from light. A finished water-based peptide serum is best refrigerated and used within a few weeks, since peptides in solution degrade over time.
Is research-grade N-Acetyl Selank Amidate an approved drug?
No. N-Acetyl Selank Amidate is a cosmetic-grade ingredient for topical formulation and research, not an approved medicine; the evidence supports only modest topical, cosmetic effects. Everything here is research and educational information, not medical advice.
New protocols & dosing updates
Reconstitution charts, new peptide protocols and safety updates — straight to your inbox. No spam, unsubscribe anytime.